Literature DB >> 17912448

Interaction of prostate specific membrane antigen with clathrin and the adaptor protein complex-2.

Oscar B Goodman1, Sonali P Barwe, Brigitte Ritter, Peter S McPherson, Ann-Jeanette Vasko, James H Keen, David M Nanus, Neil H Bander, Ayyappan K Rajasekaran.   

Abstract

Prostate-specific membrane antigen (PSMA) is an integral membrane glycoprotein expressed in prostatic epithelia and is being evaluated as a therapeutic target in prostate cancer. It undergoes constitutive receptor-mediated endocytosis via clathrin-coated pits, which is enhanced in the presence of monoclonal antibodies directed against it. We describe distinct interactions of PSMA with clathrin and the clathrin adaptor protein-2 (AP-2) complex, two components of clathrin-coated pits. The intracellular N-terminal domain of PSMA interacts with the N-terminal globular domain of clathrin heavy chain. Deletion analysis revealed an important determinant of this interaction residing within the proximal portion of the clathrin heavy chain N-terminal domain (amino acids 1-85) distinct from the clathrin binding sites of other known clathrin-binding proteins. Furthermore, PSMA interacts with the ear domain of alpha-adaptin (an AP-2 subunit), and a glutamic acid residue at position 7 in the cytoplasmic tail of PSMA is essential for this interaction. These data indicate that PSMA exhibits a high affinity, specific association with the clathrin-based endocytic machinery by distinct interactions with both clathrin and AP-2. Thus, although PSMA is a new member of the dual AP and clathrin binding proteins, its alpha-adaptin and clathrin heavy chain binding determinants are distinct from those of other members.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17912448

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  11 in total

Review 1.  Glutamate carboxypeptidase II in diagnosis and treatment of neurologic disorders and prostate cancer.

Authors:  C Bařinka; C Rojas; B Slusher; M Pomper
Journal:  Curr Med Chem       Date:  2012       Impact factor: 4.530

2.  Radiofluorination of PSMA-HBED via Al(18)F(2+) Chelation and Biological Evaluations In Vitro.

Authors:  Noeen Malik; Benjamin Baur; Gordon Winter; Sven N Reske; Ambros J Beer; Christoph Solbach
Journal:  Mol Imaging Biol       Date:  2015-12       Impact factor: 3.488

Review 3.  The therapeutic and diagnostic potential of the prostate specific membrane antigen/glutamate carboxypeptidase II (PSMA/GCPII) in cancer and neurological disease.

Authors:  James C Evans; Meenakshi Malhotra; John F Cryan; Caitriona M O'Driscoll
Journal:  Br J Pharmacol       Date:  2016-09-23       Impact factor: 8.739

Review 4.  [Molecular multimodal hybrid imaging in prostate and bladder cancer].

Authors:  T Maurer; M Eiber; B J Krause
Journal:  Urologe A       Date:  2014-04       Impact factor: 0.639

5.  A dimerized urea-based inhibitor of the prostate-specific membrane antigen for 68Ga-PET imaging of prostate cancer.

Authors:  Martin Schäfer; Ulrike Bauder-Wüst; Karin Leotta; Frederic Zoller; Walter Mier; Uwe Haberkorn; Michael Eisenhut; Matthias Eder
Journal:  EJNMMI Res       Date:  2012-06-06       Impact factor: 3.138

Review 6.  Targeted nonviral gene therapy in prostate cancer.

Authors:  Najla Altwaijry; Sukrut Somani; Christine Dufès
Journal:  Int J Nanomedicine       Date:  2018-09-25

Review 7.  More Than Meets the Eye: Scientific Rationale behind Molecular Imaging and Therapeutic Targeting of Prostate-Specific Membrane Antigen (PSMA) in Metastatic Prostate Cancer and Beyond.

Authors:  Anniina Hyväkkä; Verneri Virtanen; Jukka Kemppainen; Tove J Grönroos; Heikki Minn; Maria Sundvall
Journal:  Cancers (Basel)       Date:  2021-05-07       Impact factor: 6.639

8.  Discriminatory Role of Detergent-Resistant Membranes in the Dimerization and Endocytosis of Prostate-Specific Membrane Antigen.

Authors:  Sonja Schmidt; Birthe Gericke; Giulio Fracasso; Dunia Ramarli; Marco Colombatti; Hassan Y Naim
Journal:  PLoS One       Date:  2013-06-19       Impact factor: 3.240

9.  Hyperkalemia in patients treated with endoradiotherapy combined with amino acid infusion is associated with severe metabolic acidosis.

Authors:  Christian H Pfob; Matthias Eiber; Peter Luppa; Florian Maurer; Tobias Maurer; Robert Tauber; Calogero D'Alessandria; Benedikt Feuerecker; Klemens Scheidhauer; Armin Ott; Uwe Heemann; Markus Schwaiger; Christoph Schmaderer
Journal:  EJNMMI Res       Date:  2018-02-27       Impact factor: 3.138

10.  Development of a Single Vial Kit Solution for Radiolabeling of 68Ga-DKFZ-PSMA-11 and Its Performance in Prostate Cancer Patients.

Authors:  Thomas Ebenhan; Mariza Vorster; Biljana Marjanovic-Painter; Judith Wagener; Janine Suthiram; Moshe Modiselle; Brenda Mokaleng; Jan Rijn Zeevaart; Mike Sathekge
Journal:  Molecules       Date:  2015-08-14       Impact factor: 4.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.